Product Description
Mechanisms of Action: GUC Activator
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cardiorentis
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Heart Failure, Acute
Phase 2: Kidney Diseases|Acute Kidney Injury|Heart Failure, Acute|Hypertension, Pulmonary|Liver Cirrhosis
Phase 1: Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2020-004815-29 | P2 |
Temporarily not available |
Hypertension, Pulmonary |
2023-08-04 |
|
ULA04 | P2 |
Terminated |
Liver Cirrhosis |
2022-11-30 |
|
TRUST | P2 |
Terminated |
Acute Kidney Injury |
2022-09-26 |
|
2019-002268-28 | P2 |
Terminated |
Liver Cirrhosis |
2022-01-13 |